Galapagos CEO Interview: Independence Allows Us To Keep Innovating
Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."
You may also be interested in...
It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.